Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.GILD is in positive territory. Get the complete picture hereThe U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion.Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell Therapy sales, partially offset by higher HIV and Livdelzi (seladelpar) sales."With multiple potential product launches in 2026, the ...